6MX.F - Eidos Therapeutics, Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Currency in EUR

Valuation Measures

Market Cap (intraday) 51.28B
Enterprise Value 31.5B
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)48.05
Price/Book (mrq)8.43
Enterprise Value/Revenue 356.25
Enterprise Value/EBITDA 6-39.13

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3110.68%
S&P500 52-Week Change 3-11.36%
52 Week High 358.93
52 Week Low 320.03
50-Day Moving Average 343.43
200-Day Moving Average 344.74

Share Statistics

Avg Vol (3 month) 321
Avg Vol (10 day) 3N/A
Shares Outstanding 538.51M
Float 10.91M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec. 31, 2019
Most Recent Quarter (mrq)Dec. 31, 2019


Profit Margin -141.75%
Operating Margin (ttm)-144.06%

Management Effectiveness

Return on Assets (ttm)-13.21%
Return on Equity (ttm)-23.18%

Income Statement

Revenue (ttm)26.69M
Revenue Per Share (ttm)0.73
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)24.19M
EBITDA -38.37M
Net Income Avi to Common (ttm)-37.84M
Diluted EPS (ttm)-1.03
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)191.16M
Total Cash Per Share (mrq)4.96
Total Debt (mrq)21.26M
Total Debt/Equity (mrq)12.40
Current Ratio (mrq)18.78
Book Value Per Share (mrq)4.51

Cash Flow Statement

Operating Cash Flow (ttm)-31.65M
Levered Free Cash Flow (ttm)-16.76M